MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 5, 2008; DOI: 10.1124/mol.108.047837


0026-895X/08/7405-1203-1214$20.00
Mol Pharmacol 74:1203-1214, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.047837v1
74/5/1203    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klose, A.
Right arrow Articles by Alzheimer, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klose, A.
Right arrow Articles by Alzheimer, C.

1-[6-[[(17β)-3-Methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122) Selectively Inhibits Kir3 and BK Channels in a Phospholipase C-Independent Fashion

Angelika Klose, Tobias Huth, and Christian Alzheimer

Department of Physiology, University of Kiel, 24098 Kiel, Germany

1-[6-[[(17β)-3-Methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122 [GenBank] ) is widely used to inhibit phospholipase C (PLC)-mediated signaling, but we and others have also reported a PLC-independent block of Kir3 channels in native cells. To elaborate on this major side effect, we examined the action of U73122 [GenBank] and 1-[6-[[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-2,5-pyrollidinedione (U73343 [GenBank] ), a structurally related but not PLC-inhibiting analog, on Kir1.1, Kir2.1, or Kir3.1/3.2 channels expressed in HEK293 cells. Both compounds (10 µM) displayed an unusual degree of selectivity for Kir3, superior even to that of tertiapin, which discriminates between Kir3 and Kir2 but also inhibits Kir1.1. Recordings from mutant Kir2 and Kir3 channels showed that U73122 [GenBank] is unlikely to block Kir3 by interfering with binding of phosphatidylinositol 4,5-bisphosphate, and U73122 [GenBank] did not seem to act like a pore blocker. U73122 [GenBank] and U73343 [GenBank] also unexpectedly suppressed Ca2+-activated K+ channels of the large-conductance type (MaxiK, BK) in a PLC-independent fashion. In single-channel recordings, both compounds significantly decreased open probability of BK channels and slowed their ultrafast gating ("flickering") at very depolarized potentials. Alignment of the amino acid sequences of Kir3 and BK channels suggested that the highly selective effect of U73122 [GenBank] /U73343 is mediated by a homologous domain within the long C-terminal ends. In fact, mutations in the C-terminal region of Kir2 and Kir3 channels significantly altered their sensitivity to the two compounds. Our data strongly caution against the use of U73122 [GenBank] when exploring signaling pathways involving Kir3 and BK channels. However, the apparent binding of U73122 [GenBank] /U73343 to a common structural motif might be exploited to develop drugs selectively targeting Kir3 and BK channels.


Received April 9, 2008; accepted August 4, 2008

Address correspondence to: Dr. Christian Alzheimer, Department of Physiology, University of Kiel, Olshausenstr. 40, 24098 Kiel, Germany. E-mail: c.alzheimer{at}physiologie.uni-kiel.de







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics